Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Vistusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR known ✓ | P42345 | 20/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 2/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 1/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 1/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 1/20 | 1.00 |
| ▸ | PFKP | Q01813 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 1.00 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 1.00 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vistusertib SCHEMBL20734874 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL1214881 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL22449928 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29350053 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29397309 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| Vistusertib SCHEMBL29353400 | 1.00 | MTOR (1.00) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22449835 | 0.95 | MTOR (0.90) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL10225658 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22858573 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL22030452 | 0.94 | MTOR (0.89) | MTORPIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 454 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | SOVARGEN CO., LTD. (KR) | 2025-10-28 | — | — | US | claimed |
| US-11622965-B2 | Methods for treating lymphoid malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2023-04-11 | — | — | US | claimed |
| WO-2023039548-A1 | KINASE INHIBITORS FOR THE TREATMENT OF PROSTATE CANCER | FRED HUTCHINSON CANCER CENTER (US) | 2023-03-16 | — | — | WO | claimed |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO., LTD. (KR) | 2021-06-24 | — | — | US | claimed |
| EP-3266455-B1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING MTOR INHIBITOR | KOREA ADVANCED INST SCI & TECH (KR) | 2020-12-30 | — | — | EP | claimed |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2020-11-17 | — | — | US | claimed |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | Zhejiang DTRM Biopharma Co. Ltd. (CN) | 2020-09-17 | — | — | US | claimed |
| EP-3700532-A1 | METHODS FOR TREATING LYMPHOID MALIGNANCIES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2020-09-02 | — | — | EP | claimed |
| EP-3471735-A2 | PHARMACEUTICAL COMPOSITIONS AND THEIR USE FOR TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Zhejiang Dtrm Biopharma Co. Ltd. (CN) | 2019-04-24 | — | — | EP | claimed |
| US-20170049786-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2017-02-23 | — | — | US | claimed |
| US-20120114637-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-05-10 | — | — | US | claimed |
| EP-2427174-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | Santen Pharmaceutical Co., Ltd (JP) | 2012-03-14 | — | — | EP | claimed |
| JP-2011512395-A | — | — | 2011-04-21 | — | — | JP | claimed |
| EP-2262504-A1 | COMBINATION THERAPY 238 | AstraZeneca AB (SE) | 2010-12-22 | — | — | EP | claimed |
| WO-2010129622-A1 | MTOR PATHWAY INHIBITORS FOR TREATING OCULAR DISORDERS | MACUSIGHT, INC. (US) | 2010-11-11 | — | — | WO | claimed |
| EP-2217234-A2 | COMBINATIONS OF MEK INHIBITORS WITH MTOR INHIBITORS | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | claimed |
| WO-2009104019-A1 | COMBINATION THERAPY 238 | ASTRAZENECA AB (SE) | 2009-08-27 | — | — | WO | claimed |
| WO-2009050506-A2 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-23 | — | — | WO | claimed |
| US-20090099174-A1 | COMBINATION 059 | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11622965-B2 | Methods for treating lymphoid malignancies | BTK, BCL6, BCL6B | MTOR 995/4885PIK3CA 322/4885PIK3CD 353/4885 |
| US-20200289517-A1 | Methods for Treating Lymphoid Malignancies | BTK, BCL6, BCL6B | MTOR 995/4885PIK3CA 322/4885PIK3CD 353/4885 |
| US-20090099174-A1 | COMBINATION 059 | MTOR, RICTOR, MAPK9 | MTOR 1/4885PIK3CA 9/4885PIK3CD 34/4885 |
| US-10835524-B2 | Compositions for the treatment of pancreatic cancer and uses thereof | PIK3CA, MTOR, PIK3CD | MTOR 2/4885PIK3CA 1/4885PIK3CD 3/4885 |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 347/4885PIK3CD 100/4885 |
| US-20210186980-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 358/4885PIK3CD 146/4885 |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | MTOR, MAPKAP1, RPTOR | MTOR 1/4885PIK3CA 358/4885PIK3CD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.